Original Research
Published on 05 Jan 2026
Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2− advanced breast cancer in China
- 1,024 views
Original Research
Published on 05 Jan 2026
Systematic Review
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Review
Published on 05 Jan 2026
Systematic Review
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Review
Published on 05 Jan 2026
Systematic Review
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Systematic Review
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Mini Review
Published on 05 Jan 2026
Systematic Review
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Review
Published on 05 Jan 2026
General Commentary
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Review
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026
Original Research
Published on 05 Jan 2026